Health Economics›Neuroblastoma›High Risk

High Risk

Neuroblastoma · 4 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy

No data points — cost or PFS missing for current selection.

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
COG A3973 with Myeloablative Therapy Partial	—	R 151 461	28d	—	—	~6	~R 504 305 indirect	—
COG A3973 without Myeloablative Therapy	—	R 148 333	28d	—	—	~2	~R 250 249 indirect	—
COG ANBL0532 Regimen A Partial	—	R 102 174	36d	—	—	~6	~R 201 901 indirect	—
COG ANBL 0032 Regimen A Variant #01	—	R 2 669	25d	—	—	~6	~R 16 016 indirect	—

4 of 4 regimens shown